These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 38090230)

  • 1. Effects of Dual-Release Hydrocortisone on Bone Metabolism in Primary and Secondary Adrenal Insufficiency: A 6-Year Study.
    Hasenmajer V; Ferrari D; De Alcubierre D; Sada V; Puliani G; Bonaventura I; Minnetti M; Tomaselli A; Pofi R; Sbardella E; Cozzolino A; Gianfrilli D; Isidori AM
    J Endocr Soc; 2023 Dec; 8(1):bvad151. PubMed ID: 38090230
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bone safety of dual-release hydrocortisone in patients with autoimmune primary adrenal insufficiency.
    Bioletto F; Barale M; Parasiliti-Caprino M; Giannelli J; Campioni L; Cappiello V; Di Carlo MC; Ghigo E; Procopio M; Giordano R
    Front Endocrinol (Lausanne); 2023; 14():1234237. PubMed ID: 37766685
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of hydrocortisone replacement on bone mineral density and bone turnover markers in patients with primary adrenal insufficiency.
    Yazidi M; Danguir C; Maamer D; Oueslati I; Khiari K; Elleuch M; Feki M; Chihaoui M
    Endocr Regul; 2022 Jul; 56(3):209-215. PubMed ID: 35843715
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prednisolone is associated with a worse bone mineral density in primary adrenal insufficiency.
    Frey KR; Kienitz T; Schulz J; Ventz M; Zopf K; Quinkler M
    Endocr Connect; 2018 Jun; 7(6):811-818. PubMed ID: 29720511
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bone mineral density is not significantly reduced in adult patients on low-dose glucocorticoid replacement therapy.
    Koetz KR; Ventz M; Diederich S; Quinkler M
    J Clin Endocrinol Metab; 2012 Jan; 97(1):85-92. PubMed ID: 21994966
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Introduction: Patients with primary adrenal insufficiency receive long - term glucocorticoid replacement therapy, which may cause osteoporosis].
    Vaňuga P; Ságová I
    Vnitr Lek; 2021; 67(5):264-269. PubMed ID: 35459392
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Switching From Immediate-Release to Fractionated Dual-Release Hydrocortisone May Improve Metabolic Control and QoL in Selected Primary Adrenal Insufficiency Patients.
    Delle Cese F; Corsello A; Cintoni M; Locantore P; Pontecorvi A; Corsello SM; Paragliola RM
    Front Endocrinol (Lausanne); 2020; 11():610904. PubMed ID: 33597926
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bone mineral density and trabecular bone score in patients with 21-hydroxylase deficiency after glucocorticoid treatment.
    Gao Y; Wang O; Guan W; Wu X; Mao J; Wang X; Yu W; Nie M
    Clin Endocrinol (Oxf); 2021 May; 94(5):765-773. PubMed ID: 33301636
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Benefits of dual-release hydrocortisone treatment on central adiposity and health-related quality of life in secondary adrenal insufficiency.
    Gasco V; Giannelli J; Campioni L; Arvat E; Ghigo E; Grottoli S; Maccario M; Giordano R
    J Endocrinol Invest; 2023 Mar; 46(3):587-597. PubMed ID: 36251244
    [TBL] [Abstract][Full Text] [Related]  

  • 10. What factors have impact on glucocorticoid replacement in adrenal insufficiency: a real-life study.
    Puglisi S; Rossini A; Tabaro I; Cannavò S; Ferrau' F; Ragonese M; Borretta G; Pellegrino M; Dughera F; Parisi A; Latina A; Pia A; Terzolo M; Reimondo G
    J Endocrinol Invest; 2021 Apr; 44(4):865-872. PubMed ID: 32779106
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term outcomes of conventional and novel steroid replacement therapy on bone health in primary adrenal insufficiency.
    Guarnotta V; Di Stefano C; Giordano C
    Sci Rep; 2022 Aug; 12(1):13280. PubMed ID: 35918399
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiometabolic and psychological effects of dual-release hydrocortisone: a cross-over study.
    Dineen R; Martin-Grace J; Ahmed KMS; Frizelle I; Gunness A; Garrahy A; Hannon AM; O'Reilly MW; Smith D; McDermott J; Healy ML; Agha A; Pazderska A; Gibney J; Thompson CJ; Behan LA; Sherlock M
    Eur J Endocrinol; 2021 Feb; 184(2):253-265. PubMed ID: 33513125
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reduction in daily hydrocortisone dose improves bone health in primary adrenal insufficiency.
    Schulz J; Frey KR; Cooper MS; Zopf K; Ventz M; Diederich S; Quinkler M
    Eur J Endocrinol; 2016 Apr; 174(4):531-8. PubMed ID: 26811406
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tissue Glucocorticoid Metabolism in Adrenal Insufficiency: A Prospective Study of Dual-release Hydrocortisone Therapy.
    Dineen RA; Martin-Grace J; Ahmed KMS; Taylor AE; Shaheen F; Schiffer L; Gilligan LC; Lavery GG; Frizelle I; Gunness A; Garrahy A; Hannon AM; Methlie P; Eystein SH; Stewart PM; Tomlinson JW; Hawley JM; Keevil BG; O'Reilly MW; Smith D; McDermott J; Healy ML; Agha A; Pazderska A; Gibney J; Behan LA; Thompson CJ; Arlt W; Sherlock M
    J Clin Endocrinol Metab; 2023 Nov; 108(12):3178-3189. PubMed ID: 37339332
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Benefit of Menopausal Hormone Therapy on Bone Density and Microarchitecture Persists After its Withdrawal.
    Papadakis G; Hans D; Gonzalez-Rodriguez E; Vollenweider P; Waeber G; Marques-Vidal PM; Lamy O
    J Clin Endocrinol Metab; 2016 Dec; 101(12):5004-5011. PubMed ID: 27854548
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Trabecular bone score in the hip: a new method to examine hip bone microarchitecture-a feasibility study.
    Haeri NS; Perera S; Ferreiro I; Hans D; Greenspan SL
    Arch Osteoporos; 2022 Sep; 17(1):126. PubMed ID: 36125566
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dual-release hydrocortisone and its benefits on cognitive function and quality of sleep.
    Krekeler C; Kropp P; Blacha AK; Rahvar AH; Harbeck B
    Endocrine; 2021 Apr; 72(1):223-233. PubMed ID: 33625720
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dual-release hydrocortisone improves body composition and the glucometabolic profile in patients with secondary adrenal insufficiency.
    Jørgensen NT; Boesen VB; Borresen SW; Christoffersen T; Jørgensen NR; Plomgaard P; Christoffersen C; Watt T; Feldt-Rasmussen U; Klose M
    Endocrine; 2024 Jun; 84(3):1182-1192. PubMed ID: 38345683
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Utilization of DXA Bone Mineral Densitometry in Ontario: An Evidence-Based Analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2006; 6(20):1-180. PubMed ID: 23074491
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The impact of glucocorticoid therapy on trabecular bone score in older women.
    Paggiosi MA; Peel NF; Eastell R
    Osteoporos Int; 2015 Jun; 26(6):1773-80. PubMed ID: 25743176
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.